ChemoMetec A/S (CHEMM)

Currency in DKK
525.00
+15.00(+2.94%)
Real-time Data·
CHEMM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
510.50533.00
52 wk Range
235.20804.00
Key Statistics
Prev. Close
510
Open
510.5
Day's Range
510.5-533
52 wk Range
235.2-804
Volume
106.09K
Average Volume (3m)
64.39K
1-Year Change
-19.6018%
Book Value / Share
41.68
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CHEMM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
635.00
Upside
+20.95%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

ChemoMetec A/S News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 635.00
(+20.95% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Berenberg
Buy640.00+21.90%650.00MaintainSep 17, 2026
Berenberg
Buy650.00+23.81%900.00MaintainMar 26, 2026
Berenberg
Buy900.00+71.43%970.00MaintainFeb 23, 2026

ChemoMetec A/S Earnings Call Summary for Q4/2026

  • ChemoMetec Q4 EPS of -$1.15 missed estimates of -$0.80 by 44%; revenue of $124M slightly beat forecasts at $123.33M; shares fell 6.22% to $490.
  • Full-year revenue hit record DKK 511M, up 7% at constant FX; EBITDA margin expanded to 55.0% from 52.1%; XcytoMatic sales surged 146% YoY to DKK 68.1M.
  • FY 2026/2027 guidance set at DKK 545-575M revenue and DKK 300-313M EBITDA; excludes uncertain Roche, Tecan, Hamilton partnership revenue contributions.
  • Management adopted conservative forecasting after prior miss; expects XcytoMatic to become lead instrument by next year, driving growth alongside NC-203 platform.
  • U.S. federal shutdown hurt consumables sales; company exiting animal semen/beer/milk markets; investing heavily in software (20-25% of R&D) for platform expansion.
Last Updated: 2026-09-11, 09:46 a/m
Read Full Transcript

Earnings

Latest Release
Sep 10, 2026
EPS / Forecast
-1.52 / -0.80
Revenue / Forecast
120M / 123.33M
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 11.60%
Dividend Yield
1.34%
Industry Median 4.11%
Annualized payout
7.00
Paid annually
5-Years Growth
+56.32%
Growth Streak

CHEMM Income Statement

Compare CHEMM to Peers and Sector

Metrics to compare
CHEMM
Peers
Sector
Relationship
P/E Ratio
43.5x13.4x−0.4x
PEG Ratio
2.87−0.350.00
Price/Book
12.1x1.4x2.6x
Price / LTM Sales
17.2x2.1x3.0x
Upside (Analyst Target)
21.4%1.1%54.3%
Fair Value Upside
Unlock4.9%7.2%Unlock

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter NC-203, a high-precision cell counter designed to deliver complex cell samples; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; and XcytoMatic 40, a cell density and viability analyzer. In addition, the company provides consumables comprising cassettes, reagents, lysis, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans and training. Further, it develops XcytoMatic 30 cell counter and Xcyto 5. ChemoMetec A/S was incorporated in 1997 and is headquartered in Allerød, Denmark.

Employees
174
Market
Denmark

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
6.03M35.07%3.08B
Other Institutional Investors
-662.02K-3.85%-337.63M
Public Companies & Retail Investors
11.83M68.78%6.03B
Total
17.2M100.00%8.77B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.11.97%2,059,6301,050,411
Vanguard Capital Management, LLC4.00%688,037350,899

People Also Watch

72.70
CBRAIN
-0.68%
957.5
NKT
+3.79%
73.70
STOGR
-0.27%
98.4
GN
-0.14%
199.10
ALKb
+0.30%

FAQ

What Is the ChemoMetec (CHEMM) Stock Price Today?

The ChemoMetec stock price today is 525.00 DKK.

What Stock Exchange Does ChemoMetec Trade On?

ChemoMetec is listed and trades on the Copenhagen Stock Exchange.

What Is the Stock Symbol for ChemoMetec?

The stock symbol for ChemoMetec is "CHEMM."

Does ChemoMetec Pay Dividends? What’s The Current Dividend Yield?

The ChemoMetec dividend yield is 1.34%.

What Is the ChemoMetec Market Cap?

As of today, ChemoMetec market cap is 9.01B DKK.

What Is ChemoMetec's Earnings Per Share (TTM)?

The ChemoMetec EPS (TTM) is 11.60.

When Is the Next ChemoMetec Earnings Date?

ChemoMetec will release its next earnings report on Nov 05, 2026.

From a Technical Analysis Perspective, Is CHEMM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has ChemoMetec Stock Split?

ChemoMetec has split 0 times.

How Many Employees Does ChemoMetec Have?

ChemoMetec has 174 employees.

What is the current trading status of ChemoMetec (CHEMM)?

As of Sep 21, 2026, ChemoMetec (CHEMM) is trading at a price of 525.00 DKK, with a previous close of 510.00 DKK. The stock has fluctuated within a day range of 510.50 DKK to 533.00 DKK, while its 52-week range spans from 235.20 DKK to 804.00 DKK.

What Is ChemoMetec (CHEMM) Price Target According to Analysts?

The average 12-month price target for ChemoMetec is 635.00 DKK, with a high estimate of 715 DKK and a low estimate of 550 DKK. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +20.95% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.